You can buy or sell SAGE and other stocks, options, ETFs, and crypto commission-free!
SAGE Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. Read More The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.
52 Week High
52 Week Low
Sell-Side Remains Optimistic On Sage Therapeutics Despite Depression Drug DisappointmentSage Therapeutics Inc (NASDAQ: SAGE) shares fell more than 60% Thursday following a negative readout for its lead asset in major depressive disorder. The Analy
Sage shares sink as depression therapy fails much-awaited trial(Reuters) - Sage Therapeutics Inc said on Thursday its experimental fast-acting drug aimed at treating severe depression failed a closely-watched study, sending
Expected Feb 18, Pre-Market